Structural insights into simocyclinone as an antibiotic, effector ligand and substrate

Mark J. Buttner¹,†, Martin Schäfer²,‡, David M. Lawson³,# and Anthony Maxwell³,§

¹Department of Molecular Microbiology, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK, ²Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA and ³Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK

∗Corresponding author: Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK. Tel: +44 1603 450771; E-mail: tony.maxwell@jic.ac.uk

One sentence summary: Simocyclinones are actinomycete natural products that target bacterial DNA gyrase; structural work has revealed their molecular mode of action, aspects of their biosynthesis and the mechanism underlying their inducible export.

ABSTRACT

Simocyclinones are antibiotics produced by Streptomyces and Kitasatospora species that inhibit the validated drug target DNA gyrase in a unique way, and they are thus of therapeutic interest. Structural approaches have revealed their mode of action, the inducible-efflux mechanism in the producing organism, and given insight into one step in their biosynthesis. The crystal structures of simocyclinones bound to their target (gyrase), the transcriptional repressor SimR and the biosynthetic enzyme SimC7 reveal fascinating insight into how molecular recognition is achieved with these three unrelated proteins.

Keywords: antibiotics; Streptomyces; DNA gyrase; aminocoumarins; DNA topoisomerases; transcription factor

INTRODUCTION

The increase in resistance to antimicrobials has become a serious challenge in the 21st Century, with rising antibiotic-resistant pathogens, particularly in hospital settings, and a paucity of new agents becoming available (Boucher et al. 2009; Bush et al. 2011). It is therefore essential that we continue our search for new antibacterial compounds, particularly novel natural products, which have the possibility of exploiting new chemical space. Actinomycetes, most notably the genus Streptomyces, have proved to be a rich source of bio-active molecules, with most antibiotics in current clinical use being actinomycete natural products or their derivatives (Clardy, Fischbach and Walsh 2006). In this review, we discuss the simocyclinones, natural products that were first isolated nearly 20 years ago from Streptomyces antibioticus Tü 6040, which produces simocyclinones A1, B1, B2, C2, C4, D4, D6, D7 and D8 (Schimana et al. 2000, 2001). More recently, Kitasatospora sp. and Streptomyces sp. NRRL B-24484 have been identified as producers of the novel simocyclinones D9, D10 and D11 (Bilyk et al. 2016); representative simocyclinones are shown in Fig. 1. As most work has been carried out on simocyclinone D8 (SD8), it will be the main topic of this review.

The target of simocyclinones is the type II DNA topoisomerase, DNA gyrase (Fig. 2). DNA topoisomerases (topos) are enzymes found in all organisms that catalyze the interconversions of different topological forms of DNA, e.g. relaxed-
Figure 1. Chemical structures of simocyclinones D8, D4 and C4.

Figure 2. Schematic representation of the DNA gyrase A2B2 complex with bound G-segment DNA. Each subunit consists of an N-terminal domain (NTD) and a C-terminal domain (CTD). For reference, the DNA gyrase structure shown in Fig. 3 corresponds to a homodimer of a 55 kDa fragment of the GyrA NTD.

Supercoiled, knotted–unknotted, catenated–decatenated (Vos et al. 2011; Bush, Evans-Roberts and Maxwell 2015) and are essential for DNA replication and transcription (Wang 2002). They are classified as type I or II depending upon whether their reactions proceed via single- or double-stranded breaks in DNA, and further divided into sub-types: IA, B, C and IIA and B, depending of mechanistic and evolutionary considerations (Wang 1996; Forterre et al. 2007). DNA gyrase (the target of simocyclinones) is a type IIA topoisomerase, and the only enzyme that can catalyze the introduction of negative supercoils into DNA. It is essential in all bacteria but lacking from animals, including humans, making it an ideal target for antibiotics. The type II topoisomerase in humans, topo II, has been developed as an anti-cancer target (Pommier et al. 2010) and can relax and de-catenate DNA but cannot supercoil. Most bacteria, in addition to gyrase, have a second type II enzyme, topo IV, which is also a relaxing/decatenating enzyme, and is also a target for antibiotics.

DNA gyrase consists of two subunits, GyrA and GyrB, which form an A2B2 complex in the active enzyme (Fig. 2; Collin, Karkare and Maxwell 2011; Bush, Evans-Roberts and Maxwell 2015). The supercoiling reaction involves the wrapping of DNA around the A2B2 complex and the passage of one segment of DNA, termed the ‘T’ or ‘transported’ segment, through a double-stranded break in another, the ‘G’ or ‘gate’ segment. Catalytic supercoiling requires the hydrolysis of ATP. As this reaction proceeds via transient double-strand breaks in DNA, agents that can stabilize the broken DNA intermediate, such as the fluoroquinolones, are very effective antibacterial agents. A number of other compounds inhibit gyrase (and other topoisomerases) via this ‘cleavage-complex stabilization’ mechanism (Collin, Karkare and Maxwell 2011; Bush, Evans-Roberts and Maxwell 2015). In addition, gyrase and other type II topoisomerases can be inhibited by compounds that act at the ATP-binding site (Maxwell and Lawson 2003); this includes aminocoumarin antibiotics, such as novobiocin. As will be shown below, the inhibition of gyrase by simocyclinones occurs by a different, previously unknown, mechanism: they prevent the enzyme from binding DNA. It is possible that this mode of action can be exploited towards the development of novel, clinically relevant antibiotics. It is interesting to note that there are a number of peptide and protein inhibitors that exhibit the three mechanisms of gyrase inhibition (Collin, Karkare and Maxwell 2011). For example, microcin B17, CcdB and ParE can stabilize the cleavage complex, MpfA and Qnr proteins seem to prevent DNA binding, and FicT proteins modify GyrB and prevent ATPase activity (Harms et al. 2015).

Simocyclinones (D4 and D8) were discovered during the search for novel secondary metabolites from Streptomyces strains derived from soil samples (Schimana et al. 2000). These compounds showed antibiotic activity against certain Gram-positive bacteria and cytotoxic effects on tumor cell lines. By varying microbial growth and fermentation conditions the yield of these compounds was analyzed and optimized (Theobald, Schimana and Fiedler 2000; Schimana et al. 2001). Using 2D NMR, the structures of SD4 and SD8 were determined (Holzenkampfer et al. 2002) and shown to consist of an aminocoumarin moiety linked via a tetaene linker and olivose sugar to an angucyclinone polyketide moiety (Fig. 1). The presence of an aminocoumarin group and the discovery that some of the biosynthetic genes were related to those of the ‘classical’ aminocoumarin
antibiotic novobiocin (Galm et al. 2002; Trefzer et al. 2002; see below), suggested that these compounds were likely to target bacterial DNA gyrase and that this was the likely cause of their antibacterial activity.

Simocyclinones have been studied most intensively as gyrase-inhibiting antibiotics, but the second section of this review covers the role of SD8 as an effector molecule controlling the activity of a transcription factor called SimR, responsible for linking the biosynthesis and export of SD8 in the producing organism, S. antibioticus. In addition, the SD8 precursor, 7-oxo-SD8, has been thoroughly characterized as a substrate for the enzyme SimC7, which reduces a carbonyl to a hydroxyl group at the C-7 position in the angucyclinone moiety of the molecule. This enzymatic step, which is critical because it converts an almost inactive precursor into the mature antibiotic, is covered in the third and final section of this review.

SIMOCYCLINONES AS ANTIBIOTICS

Activity of simocyclinones against bacteria

In general, the antibiotic activity of simocyclinones was found to be relatively weak, except against some Gram-positive bacterial species, for example Bacillus brevis (MIC 10 μg/ml) and Streptomyces viridochromogenes (MIC 1 μg/ml) (Schiman et al. 2000). Little activity was detected against Gram-negative bacteria. This is almost certainly due to the inability of simocyclinones to penetrate the outer membrane, since its mutants of E. coli, which are specifically compromised in outer membrane integrity, become sensitive to SD8 (Edwards et al. 2009b), although multidrug efflux pumps like AcrB may also contribute to resistance (Oppegard et al. 2009). However, it has been pointed out that most of these susceptibility tests have been carried out using stock lab strains, and SD8 has shown more promising activity against some clinical isolates of E. coli and Klebsiella pneumoniae (Richter et al. 2010). More recently, the discovery of new simocyclinones (Bilyk et al. 2016) and the capacity for engineering novel compounds, as has been carried out with the classical aminocoumarins (Heide et al. 2008; Heide 2009, 2014) and to a limited extent with simocyclinones (Anderle et al. 2007a,b), has raised the possibility of compounds with increased antibacterial potency. However, given that SD8 has been shown to inhibit human top II (Flatman et al. 2005; Sadig et al. 2009), the potential for mammalian toxicity must be borne in mind.

How simocyclinones inhibit DNA gyrase

The similarity between the structures of simocyclinones (Fig. 1) and those of the classical aminocoumarins led to the expectation that simocyclinones would inhibit bacterial DNA gyrase by competitively binding to the ATPase active site in the GyrB subunit. It was shown that simocyclinone D8 (and D4) did indeed inhibit DNA supercoiling catalyzed by E. coli gyrase but, surprisingly, also inhibited DNA relaxation (Flatman et al. 2005), an ATP-independent reaction. Moreover, ATPase assays showed that SD8 and SD4 did not inhibit this reaction under conditions where novobiocin was effective. The most common mode of action of topoisomerase-targeted drugs (e.g. fluoroquinolones) is the stabilization of the enzyme-DNA cleavage complex. It was shown that SD8 did not act in this way but was found to antagonize the ability of fluoroquinolones, and other agents, to induce cleavage-complex formation (Flatman et al. 2005).

Taken together, these data suggested that simocyclinones might interfere with the binding of gyrase to DNA rather than to ATP. This was directly tested using surface-plasmon resonance (SPR) in which DNA was tethered to the chip surface and the binding of gyrase monitored in the absence and presence of SD8 (Flatman et al. 2005). The presence of SD8 at relatively low concentrations (50 nM) blocked DNA binding. When different domains of gyrase were examined for their ability to bind SD8 using SPR and isothermal titration calorimetry (ITC), it was found that interaction occurred only with the N-terminal domain of GyrA (Flatman et al. 2005), which was already known to contain the binding site for the G-segment DNA (Morais Cabral et al. 1997). These biochemical and biophysical experiments therefore supported the idea that simocyclinones act by binding to the GyrA subunit at a DNA-binding site to prevent the binding of the enzyme to DNA; a completely novel mode of action. This idea was later corroborated by X-ray crystallography (Edwards et al. 2009b, Hearnshaw et al. 2014), see below. Binding of SD8 to the N-terminal domain of GyrA was also seen using circular dichroism experiments (Sissi et al. 2010); this method also showed evidence for a second binding site in the C-terminal domain of GyrB, albeit of lower affinity than the GyrA-binding site. Subsequent ITC experiments (Hearnshaw et al. 2014) also found evidence for a binding site in GyrB, but estimated that it was ∼1000-fold weaker than the GyrA site; it is unlikely that the GyrB site contributes to the activity of simocyclinones.

SD8 has also been found to inhibit E. coli top II and human top II, albeit with a lower potency than against gyrase (Flatman et al. 2005; Sadig et al. 2009). In other work, SD8 was found to also inhibit S. aureus gyrase, but was much less effective against top II from E. coli and S. aureus (Oppegard et al. 2009). S. aureus gyrase was found to be 3–4-fold less sensitive to SD8 than E. coli gyrase. Elsewhere, it was found that the difference in SD8 potencies between these enzymes was ∼20-fold (Alt et al. 2011); however, it should be stressed that the absolute IC50 values are likely to be affected by assay conditions, which differ between the two enzymes. Taken together, it seems that gyrase is the preferred target for simocyclinones, and that they act by binding to the GyrA subunit of gyrase preventing the binding of DNA.

How simocyclinone D8 binds to gyrase

Biochemical and biophysical data (described above) strongly suggested that the simocyclinones bind to GyrA in a region of the protein involved in DNA binding. This proposal was confirmed by X-ray crystallography. Crystallization trials using simocyclinone D8 (SD8) and the N-terminal domain of the DNA gyrase A protein (GyrA59), whose structure was already known (Morais Cabral et al. 1997), gave diffracting crystals (Edwards et al. 2009a). This first structure (initially solved at 2.6-Å resolution) revealed a tetramer of GyrA59 that consisted of two GyrA59 dimers crosslinked by four molecules of SD8 (Edwards et al. 2009b). Two binding pockets were observed for SD8 in each subunit, both lying within the DNA-binding `saddle’ (Morais Cabral et al. 1997) of the GyrA59 dimer, one accommodating the aminocoumarin moiety and the other accommodating the angucyclinone moiety. Selection of spontaneous SD8-resistant E. coli mutants showed that the mutations occurred in both pockets, corroborating the crystal structure (Edwards et al. 2009b). Further site-directed mutations also supported the structure, while others could not be fully rationalized (see below), suggesting that this structure might not reflect the situation in vivo. Although the crystal structure showed a protein tetramer, it was suspected that this dimer-dimer interaction was stabilized in the crystal and may not represent the physiologically relevant form of the complex.
Figure 3. (a) Structure of E. coli DNA GyrA homodimer (55 kDa N-terminal fragment) with two molecules of SD8 bound; one subunit is colored blue and the other in yellow; the SD8 molecules are shown in two shades of green (PDB accession number 4CKL). A DNA duplex taken from a superposed structure of a Staphylococcus aureus gyrase-DNA-drug complex (PDB accession number: 2XCS) is also shown in pink to illustrate that SD8 would block the interaction of G-segment DNA with the DNA-binding ‘saddle’. (b) Top view of panel a, looking down the dimer 2-fold axis. (c) Enlarged view of the boxed region shown in panel b, with the SD8 ligands in stick representation with atom coloration (carbon, green; oxygen, red; nitrogen, blue; chlorine, gray). This clearly shows that the antibiotic spans the dimer interface with distinct binding pockets for the terminal angucyclinone (ANG) and aminocoumarin (AC) groups. (This figure and the other structural figures were prepared using CC4MG; McNicholas et al. 2011.)

Figure 4. Schematic representation of the SD8-binding pocket of GyrA showing all residues within 4 Å of the ligand, as revealed in the crystal structure of the GyrA-SD8 complex (PDB accession number 4CKL). One subunit is shown in blue and the other in yellow. Hydrogen bonds are indicated by dotted lines; van der Waal contacts are indicated by orange arcs, and water molecules are shown as filled blue circles labeled ‘W’. For clarity, all hydrogens have been omitted.

Analysis of the SD8-GyrA59 complex using nanoelectrospray ionization mass spectrometry showed that the tetrameric species observed in the crystal could be reproduced in solution, but only at high SD8 concentrations, while at lower concentrations, a dimeric species was present with two SD8 molecules bound per dimer; this result was potentially at odds with the previous structural data (Edwards et al. 2009b). Further mass spectrometry suggested that the binding of SD8 to the protein dimer showed strong allosteric cooperativity (Edwards et al. 2011). A subsequent crystal structure of a shorter version of the N-terminal domain of GyrA (GyrA55), which lacks residues that stabilize dimer–dimer interactions in the tetramer, revealed a discrete protein dimer with two SD8 molecules bound (Fig. 3; Hearnshaw et al. 2014). This structure, solved at 2.05-Å resolution, proved to be entirely consistent with all the mutations to SD8 resistance that had been previously made or selected (Edwards et al. 2009b); additional mutants made in response to the revised structure were also shown to be consistent (Hearnshaw et al. 2014). In addition to the new structure being dimeric, rather than tetrameric, the conformation of SD8 is significantly different, compared with the earlier structure: the orientation of the aminocoumarin within the aminocoumarin pocket is somewhat different, while the angucyclinone ‘pocket’ has shifted such that it now spans the interface between the two monomers.
(Fig. 4) and thus could provide a structural explanation for the cooperative binding observed by mass spectrometry. This new position for the angucyclinone group suggests that the binding of SD8 effectively ‘staples’ the GyrA dimer closed so inhibiting the conformational changes that need to occur upon DNA binding and cleavage (Hearnscheid et al. 2014).

The SD8-binding site on gyrase is close to the binding site of the fluoroquinolone antibiotics (Laponogov et al. 2009; Bax et al. 2010; Laponogov et al. 2010), raising the possibility of generating hybrid compounds. To this end, a series of ciproflouxacin-aminocoumarin hybrids has been synthesized, designed to bind to the aminocoumarin pocket of SD8 and to the fluoroquinolone pocket (Austin et al. 2016); some of these compounds retain good inhibitory activity against gyrase. It remains to be seen whether such compounds can be developed as viable antibiotics. Also flavone-base analogs of simocyclinones have been made in order to bind to a hydrophobic cleft in the protein and further stabilize binding (Verghez et al. 2013). Although some of these compounds are effective gyrase inhibitors, they also stabilize the gyrase-DNA cleavage complex and probably act via a mechanism involving DNA intercalation, i.e. they do not bind at the intended site.

Taken together, we conclude that simocyclinones bind to the A subunit of DNA gyrase, in a region that is normally occupied by the G-segment DNA (Figs 2–4) and prevent the initial interaction of DNA with the enzyme and thus all the ensuing catalytic events. This is quite distinct from the mode of action of fluoroquinolones (cleavage-complex stabilization) and aminocoumarins (competitive inhibitors of ATP binding) and raises the possibility of developing other agents that use this mode of action, which would be less likely to be cross-resistant to known antibiotics.

SIMOCYCLINONE D8 AS A TRANSCRIPTION FACTOR EFFECTOR MOLECULE

SD8 has been studied most intensively as a gyrase-inhibiting antibiotic. However, it has also been characterized as an effector molecule controlling the activity of a transcription factor called SimR, responsible for linking the biosynthesis and export of SD8 in the producing organism, S. antibioticus (Le et al. 2009, 2011a,b). It is perhaps under-appreciated that antibiotics are often potentially toxic to the organisms that produce them (Cundliffe 1989; Hopwood 2007). Therefore, producing organisms must have mechanisms to ensure that the antibiotic export machinery is in place when antibiotic biosynthesis begins. The relevant mechanism in the simocyclinone producer is specified by two adjacent genes, simR and simX, which sit within the simocyclinone (sim) biosynthetic gene cluster (Galm et al. 2002; Trefzer et al. 2002; Le et al. 2009). The SimR and SimX proteins resemble the TetR/TetA repressor/efflux pump pair found in a number of human pathogens, which confer resistance to clinically important tetracyclines (Chopra and Roberts 2001). SimX is an efflux pump, a member of the major facilitator superfamily, which exports simocyclinone from the producing organism. simX transcription is repressed by SimR, a TetR-family transcriptional regulator (TFR) that binds to two separate operators in the intergenic region between the divergently transcribed simR and simX genes (Le et al. 2009). Simocyclinone abolishes DNA-binding by SimR, thereby derepressing transcription of the simX efflux pump gene, and this provides the mechanism that couples the biosynthesis of simocyclinone to its export. It was also shown that the biosynthetic intermediate simocyclinone C4 (SC4; Fig. 1), could dissociate SimR from its operators (Le et al. 2009). Subsequently, crystal structures of SimR alone (apo; 1.95-Å resolution) (Le et al. 2011b), in complex with its operator DNA (2.99-Å resolution) (Le et al. 2011a), and in complex with either SD8 or SC4 (both 2.3-Å resolution) (Le et al. 2011b), showed how SimR binds its effector ligand and how ligand binding prevents SimR from binding to its operator DNA. Unsurprisingly, there is no similarity between the ligand-binding pockets in gyrase and SimR.

How SimR binds SD8

TFRs function as homodimers, with each subunit having two domains, an N-terminal DNA-binding domain (DBD) containing a helix-turn-helix (HTH) motif, and a C-terminal ligand-binding domain (LBD) (Ramos et al. 2005; Yu et al. 2010; Cuthbertson and Nadwell 2013). The ligand–binding pocket of SimR is unusual; in other characterized TFRs, one ligand-binding pocket is typically contained within each subunit and so, for example, in the closely related protein, ActR, there is only one ligand contact with the second subunit (Willems et al. 2008), while in TetR itself there is none (Orth et al. 2000). In contrast, the ligand-binding pocket in SimR spans the two protein subunits, with the angucyclinone of SD8 bound in one subunit, while the olivose sugar, tetaene and aminocoumarin parts of the molecule are bound in the other (Le et al. 2011b) (Figs 5 and 6). This split binding pocket is ~30 Å in length, with SD8 bound in an extended conformation. Although SD8 has 19 atoms that could potentially participate in hydrogen bonding, there are only five direct hydrogen bonds between SimR and SD8, three with the aminocoumarin and two with the angucyclinone (Fig. 6). However, the dearth of hydrogen bonding is compensated for by extensive van der Waals contacts with the protein along the length of the ligand (Fig. 6). The way cognate ligands are bound by TFRs is highly variable. For example, when the SimR-SD8 structure is compared with that of the complex between the closely related TFR protein ActR and its cognate ligand, the antibiotic actinorhodin, the long axis of the actinorhodin molecule lies almost perpendicular to that of SD8 in the SimR–SD8 structure (Willems et al. 2008; Le et al. 2011b).

How simocyclinone D8 prevents SimR from binding DNA

Available evidence suggests that apo-TFRs sample a range of conformations in solution and that ligand binding simply captures one of these conformations, rather than inducing the conformational change (Reichheld, Yu and Davidson 2009; Yu et al. 2010; Cuthbertson and Nadwell 2013). SimR-apo did not crystallize in its DNA-binding form (apparent from the distance between its recognition helices), and indeed this is generally true of TFR apo-proteins (Yu et al. 2010). However, comparison of the SimR-apo, SimR-SD8 and SimR-DNA structures provided clear insight into the likely mechanism of ligand-mediated derepression.

The ligand-binding sites of TFRs are remote from their DBDs and derepression generally involves allosteric mechanisms (Ramos et al. 2005; Yu et al. 2010; Cuthbertson and Nadwell 2013). Ligand-bound and DNA-bound structures have been determined for several TFRs, including QacR, DesT, CgmR and TetR itself, and in these cases conformational changes appear to be transmitted largely within the same subunit (Orth, Saenger and Hinrichs 1999; Orth et al. 2000; Schumacher et al. 2001; 2002; Itou et al. 2010; Miller et al. 2010). Specifically, they suggest that ligand binding traps a conformational state in which the DBD (in
Figure 5. Comparison of the SimR-SD8 (a,b,c) and SimR-DNA (d,e,f) structures with one SimR subunit shown in blue and the other shown in yellow. The two recognition helices are highlighted in magenta and bound SD8 molecules are shown in green. Note that the ligand-binding pocket in SimR spans the two protein subunits, with the angucyclinone (ANG) end of SD8 bound in one subunit while the aminocoumarin (AC) end is bound in the other such that SD8 skewers the two subunits. Note also that in the apo form of SimR (structure not shown), Arg122 is buried in its cognate subunit; however, in the SimR-SD8 complex, each copy of this residue (shown as red sticks) projects across the dimer interface into a pocket in the surface of the opposing subunit. Arg122 is not ordered in the SimR-DNA structure. (PDB accession numbers: SimR-SD8: 2Y30; SimR-DNA: 3ZQL; SimR-apo: 2Y2Z).

particular the HTH motif) is repositioned relative to the LBD such that the two recognition helices in the homodimer are too far apart to bind appropriately in consecutive major grooves of the DNA. In contrast, comparison of the repressive SimR-DNA structure with the derepressed SimR-SD8 structure shows that the relative dispositions of the LBDs and DBDs within each individual SimR subunits remain essentially unchanged on ligand binding. Instead, SD8 binding captures a conformation in which there is a rigid-body rotation of one SimR subunit relative to the other, and this rigid-body rotation moves the recognition helices ~5 Å further apart in the derepressed (SD8-bound) state, preventing DNA binding (Fig. 7). It may well be significant that the ligand-binding sites in the previously characterized TFRs are contained almost entirely within individual subunits, whereas the ligand-binding pocket in SimR spans the two subunits.

Two helices of the SimR LBD (α9-α10) form a wrapping arm that folds around the LBD of the opposing subunit (Figs 5 and 7). These two helices form the end of the ligand-binding pocket responsible for binding the angucyclinone of SD8 (Figs 5, 6 and 7), and the wrapping arm changes conformation in the ligand-bound state. Only five reciprocal inter-subunit hydrogen bonds (i.e. 10 in total) are maintained between the repressive DNA-bound conformation and the derepressed ligand-bound structure, and all five of these link the wrapping arm with the LBD of the other subunit. As a consequence, when the subunits rotate in the ligand-bound form, the wrapping arm moves with them. Because the ligand-binding pocket passes through both subunits, SD8 effectively skewers the dimer, rigidifying the complex, and because it is a relatively hydrophobic molecule, SD8 contributes to the hydrophobic core of the SimR dimer, stabilizing the overall structure. In addition, in the apo and DNA-bound structures, the two SimR subunits present essentially flat surfaces to one another, allowing them to rotate relative to each other. In contrast, in the SD8-bound form, the sidechain of Arg122 from each subunit projects across the dimer interface into a pocket in the surface of the opposing subunit, potentially acting as locating pins to lock the subunits together (Fig. 5).

The biosynthetic intermediate simocyclinone C4 (SC4) lacks the aminocoumarin ring present in the mature antibiotic (Fig. 1) and is essentially inactive as a DNA gyrase inhibitor; the SD8 IC₅₀ is 0.1 μM, whereas the SC4 IC₅₀ is >100 μM (Edwards et al. 2009b). However, despite the absence of the aminocoumarin ring, SC4 binds SimR and prevents it from binding DNA (Le et al. 2009). The
structure of the SimR-SC4 complex has also been determined (Le et al. 2011b). Comparison of the SD8-SimR and SC4-SimR structures shows that the two molecules bind SimR in the same way, meaning the parts common to both molecules (the angucyclinone, tetraene and olivose sugar) occupy equivalent positions in the binding pocket. SC4 is slightly less effective than SD8 at derepressing SimR in vitro (Le et al. 2009) and this is probably a consequence of the fewer favorable interactions that SC4 makes with the protein, due to the absence of the aminocoumarin. These results show that a pathway intermediate that is not an active antibiotic can induce expression of the efflux pump prior to the build-up of a toxic concentration of the potentially lethal mature antibiotic (Hopwood 2007; Tahlan et al. 2007; Le et al. 2009).

**7-OXO-SIMOCYCLINONE D8 AS A SUBSTRATE**

While the functions of most of the biosynthetic enzymes encoded within the S. antibioticus sim cluster have been predicted (Galm et al. 2002; Trefzer et al. 2002), the biosynthetic pathway remains largely uncharacterized experimentally. This lack of knowledge about the biosynthesis of simocyclinones is well illustrated by the tetraene moiety. Trefzer et al. (2002) proposed that the tetraene linker would be the product of the large modular type I polyketide synthase (PKS), SimC1ABC, working in trans with two monofunctional enzymes, SimL and SimC7. Yet when Bilyk et al. (2016) sequenced the Kitasatospora sp. and Streptomyces sp. NRRL B-24484 biosynthetic clusters, there were no type I PKS genes present, and the tetraene was instead shown to be synthesized by an iterative type II PKS. This type II PKS is also present in S. antibioticus, leaving the role of the type I PKS unknown. To date, only two biosynthetic enzymes have been characterized biochemically: SimL and SimC7. SimL catalyses the presumed last step in the pathway, acting as an amide bond-forming ligase that attaches the aminocoumarin to the tetraene linker (Luft et al. 2005; Pacholec et al. 2005; Anderle et al. 2007b).

As noted above, the second enzyme, SimC7, was originally proposed to be involved in the biosynthesis of the tetraene linker. It was subsequently shown to be a NAD(P)H-dependent ketoreductase that catalyzes the reduction of a carbonyl to a hydroxyl group at the C-7 position of the angucyclinone, highlighting the dangers of relying on speculative gene annotations (Fig. 8; Schäfer et al. 2015). This enzymatic step is essential for antibiotic activity, converting the almost inactive 7-oxo-SD8 (IC50 ~ 50–100 μM) into the potent gyrase inhibitor SD8 (IC50 ~ 0.1–0.6 μM) (Schäfer et al. 2015). Based on the intermediates produced by S. antibioticus, it seems the biosynthesis of SD8 starts with assembly of the angucyclinone, followed by the attachment of the olivose sugar, and then the tetraene linker, and finally the aminocoumarin (i.e. as drawn in Figs 1 and 8, SD8 is assembled from right to left) (Schimana et al. 2001). Therefore, the natural substrate of SimC7 is probably a 7-oxo angucyclinone intermediate lacking the attached olivose sugar, tetraene linker and aminocoumarin, an intermediate that is detectable only in ΔsimC7 mutants (Schäfer et al. 2015). Nevertheless, the enzyme readily accepts as a substrate the full-length intermediate 7-oxo-SD8, the product made by ΔsimC7 mutants (Schäfer et al. 2015).
SimC7 is a member of the short-chain dehydrogenase/reductase (SDR) superfamily. These proteins have diverse biochemical activities, including functioning as dehydratases, reductases, epimerases, dehydrogenases and decarboxylases (Kallberg, Oppermann and Persson 2010; Persson and Kallberg 2013). Classical SDR enzymes have a characteristic Ser-Tyr-Lys catalytic triad in their active site, in which the latter two residues form a YxxK motif. The conserved tyrosine acts as a central acid-base catalyst that donates a proton to the substrate. The adjacent lysine serves to lower the pKa of the tyrosine hydroxyl group and often contributes directly to a proton relay mechanism. Lastly, the hydroxyl group of the serine polarizes the carbonyl group of the substrate (Kavanagh et al. 2008). The catalytic mechanism of SimC7 was investigated because it shares little sequence similarity with other characterized ketoreductases, even with functionally analogous polyketide ketoreductases involved in the biosynthesis of related angucyclinone antibiotics. Most of all, alignments of SimC7 with other SDR proteins suggested that SimC7 lacked the classical catalytic triad, including the tyrosine that acts as the central acid-base catalyst in classical SDR proteins. This possibility was investigated by determining the structures of SimC7 alone (apo; 1.6 Å resolution), the binary complex with NADP$^+$ (1.95 Å resolution) and the ternary complex with both NADP$^+$ and 7-oxo-SD8 (1.2 Å resolution) (Schäfer et al. 2016). As might be expected, there is no similarity between the simocyclinone-binding pockets in gyrase, SimR and SimC7.

SimC7 has two domains (Fig. 9), a larger Rossmann-fold domain that binds NADP$^+$ and a smaller substrate-binding domain that is characteristic of the so-called extended SDR subfamily (Kavanagh et al. 2008). This latter domain contains a ‘lid’ motif consisting of two anti-parallel $\alpha$-helices that sits over the active site. The apo, binary and ternary SimC7 structures are very similar except for the orientation of this lid, which closes somewhat over the bound substrate (maximum $C_{\alpha}-C_{\alpha}$ shift 5.35 Å). The underside of the lid forms part of the tight, highly hydrophobic substrate binding pocket (Fig. 9) that provides the environment needed for catalysis (Schäfer et al. 2016).

How SimC7 binds 7-oxo-SD8

In the SimC7 ternary complex with substrate and NADP$^+$ bound, the angucyclinone ring system of 7-oxo-SD8 binds adjacent and parallel to the nicotinamide ring of the cofactor (Fig. 9c), where it adopts an essentially planar conformation. This differs from the conformations seen in the SimR-SD8 and gyrase-SD8 complexes, where the A-ring of the angucyclinone in SD8 is tilted upwards towards the epoxide (Le et al. 2011b, Hearnshaw et al. 2014; Schäfer et al. 2016). The substrate pocket has several distinctive characteristics (Fig. 9). The pocket is very hydrophobic and highly constricted in shape, features that are likely to enforce the planar conformation on the angucyclinone ring system. Strikingly, within the hydrophobic pocket, 7-oxo-SD8 is bound by just one direct hydrogen bond, connecting the side-chain of Ser95 and the C-7 carbonyl oxygen of the angucyclinone (Fig. 10; Schäfer et al. 2016). However, even this single hydrogen bond is not required for enzymatic activity, since a constructed S95A variant shows almost wild-type levels of...
substrate conversion (Schäfer et al. 2016). Thus, although this hydrogen bond may help to position the C-7 carbonyl above the C-4 position of the nicotinamide ring ready for direct hydride transfer, and provide additional polarization of the C-7 carbonyl group, as proposed for the structurally equivalent Ser or Thr residues in classical SDR proteins (Kavanagh et al. 2008; Kallberg, Oppermann and Persson 2010; Persson and Kallberg 2013), neither proposed effect is crucial for catalysis. As discussed above, the natural substrate for SimC7 is probably a 7-oxo angucyclinone intermediate lacking the olivose sugar, tetraene linker and aminocoumarin. Consistent with this suggestion, only the angucyclinone is buried in the active site of SimC7, with the rest of the molecule projecting out of the enzyme (Fig. 9). Indeed, the aminocoumarin and roughly half of the tetraene linker are not resolved in electron density.

How SimC7 converts 7-oxo-SD8 into SD8

The structures confirmed the prediction made from sequence alignments that SimC7 lacks a canonical SDR Ser-Tyr-Lys catalytic triad (Schäfer et al. 2016). While the serine is conserved (Ser95), the other two residues (the YxxxK motif), including the key tyrosine residue that acts as the acid/base catalyst in classical SDR proteins, are replaced by Ile108 and His112, respectively (Fig. 11). The structures also demonstrate that there is no alternative residue that could act as an acid/base catalyst, and instead suggest that SimC7 has a novel reaction mechanism (Schäfer et al. 2016). This unusual mechanism does not depend on catalytic residues in the protein, but instead exploits the chemical characteristics of 7-oxo-SD8 itself, and is thus a new example of substrate-assisted catalysis (Dall’Acqua and Carter 2000). In the first step, the hydrophobic environment of the substrate-binding pocket and the juxtaposition of the quinone-like C-ring and the phenyl-like D-ring of the angucyclinone promote the formation of an intramolecular hydrogen bond between the proton on the C-8 hydroxyl and the oxygen of the neighboring C-7 carbonyl (Fig. 11b). This intramolecular hydrogen bond polarizes the carbonyl, enhancing the electrophilicity of C-7 and making it a good acceptor for hydride attack from the 4-pro-S position of the nicotinamide ring, which is only 3.0 Å away. Then, internal proton transfer from the neighboring C-8 hydroxyl group forms the C-7 hydroxyl group, generating a phenolate intermediate where the aromatic D-ring stabilizes the negative charge on the C-8 oxygen. In the second step of the reaction, the phenolate intermediate leaves the substrate-binding pocket and the C-8 hydroxyl group re-forms by abstracting a proton from bulk water (Fig. 11b), something that cannot happen within the confines of the active site. The hydrophobic active site cavity would accelerate expulsion of the charged phenolate intermediate created during catalysis. Lastly, the direct hydride attack from below the angucyclinone explains why simocyclinones have 7S-stereochemistry. In summary, the SimC7 mechanism involves the intramolecular transfer of a substrate-derived proton to generate a phenolate intermediate, and this obviates the need for proton transfer from a canonical SDR active-site tyrosine.

Why 7-oxo-SD8 almost inactive as a DNA gyrase inhibitor?

It is striking that SD8 is very potent as a gyrase inhibitor (IC50 ∼ 0.1–0.6 μM) and yet 7-oxo-SD8 is almost inactive (IC50 ∼ 50–100 μM) (Schäfer et al. 2015). Why does such a small structural difference, the presence of a carbonyl group at the C-7 position in 7-oxo-SD8 (Fig. 8), have such a drastic effect on the antibiotic activity of the molecule? The likely answer becomes
Figure 9. (a) and (b) Crystal structure of the SimC7 ternary complex with NADP$^+$ and 7-oxo-SD8. The nucleotide-binding domain, the substrate-binding domain and the lid motif are shown in yellow, blue and magenta, respectively. NADP$^+$ is shown in pink and 7-oxo-SD8 is shown in green. For the latter, only the crystallographically resolved atoms are shown, i.e. the angucyclinone, the olivose and roughly half of the tetraene linker. (c) Close-up showing the active site of the ternary complex including the Ser95-Ido108-His112 catalytic triad residues, and Asn137, which is important in maintaining the syn-conformation of the cofactor. C-4 of the cofactor nicotinamide ring and C-7 of the substrate are highlighted by black spheres, which are 3 Å apart, indicating that the substrate is exactly positioned for direct hydride transfer. (d) Cross-section through the active site pocket, showing how tightly the cofactor (pink) and substrate (green) are bound. For clarity, only the nicotinamide ribosyl moiety of the cofactor is shown in panel d, and only the angucyclinone moiety of the substrate is shown in panels c and d (PDB accession number: 5L4L).

Clear from analysis of the structure of the GyrA-SD8 complex: both the C-7 and C-8 hydroxyls are involved in a hydrogen bonding network that helps secure the angucyclinone in its binding pocket (Fig. 4). However, in 7-oxo-SD8, an intramolecular hydrogen bond between the C-7 carbonyl and the C-8 hydroxyl is preferred over these intermolecular interactions and this simultaneously breaks the direct contact between the angucyclinone and His80 and the indirect contacts with Pro79 and Arg121 (Fig. 4). His80, in particular, is known to play a crucial role in binding simocyclinone, since mutating this residue to alanine causes a 230-fold increase in the IC$_{50}$ of SD8 for gyrase (Edwards et al. 2009b). In addition, the presence of a carbonyl group at C-7 would alter the overall conformation of the angucyclinone ring system, which may well affect other bonding interactions with GyrA.

CONCLUDING REMARKS

In the three different systems we have described in this review, the interaction of the ligand with the protein has entirely different downstream consequences. For gyrase, it results in inhibition, leading to cell death, for SimR, it results in derepression, leading to antibiotic export, and for SimC7, it results in catalysis, leading to potentiation of an antibiotic. Given that SimC7 is an enzyme, the interaction with the ligand is transient, whereas the interaction with gyrase and SimR will be much longer-lived.
The extensive nature of these double-headed interactions leads to very tight binding, commensurate with the physiological consequences. Indeed, molecules lacking either the angucyclinone or the aminocoumarin bind much more weakly to DNA gyrase and, as a consequence, the potency of SD8 as an antibiotic is severely compromised through loss of either ‘warhead’ (Edwards et al. 2009b). The proportion of hydrogen bonds is highest for the complex with gyrase because the binding site is largely solvent-exposed and would otherwise interact with the G-segment DNA, which is polar. In SimR, the ligand-binding site threads through the hydrophobic core of the homodimer, and so the interactions are dominated by van der Waals contacts. In contrast, in the 7-oxo-SD8 complex with SimC7, only the angucyclinone interacts with the enzyme, this being consistent with the site of ketoreduction and the expectation that the natural substrate in vivo is the angucyclinone alone. Given the necessity to precisely position the SimC7 substrate for catalysis, the dearth of hydrogen bonds seems counterintuitive. Indeed, a Ser95 to Ala substitution that removes the only hydrogen bond shows that even this is dispensable. However, the necessity to provide a hydrophobic environment for efficient catalysis would be consistent with a paucity of hydrogen bonding partners and bound water molecules. Instead, the highly constrained nature of the SimC7 active site is a key factor in sterically guiding the substrate to its catalytically competent position adjacent to the cofactor with hydride donor and hydride acceptor atoms juxtaposed. The transient nature of this interaction would be promoted by the negative charge that develops on the phenolate intermediate, which would be unfavorable in the hydrophobic active site, and possibly also by the increased puckering of the angucyclinone ring system that would occur when the C7 keto group is reduced to a hydroxyl.

Finally, although SD8 itself is not viable as a clinical antibiotic, due at least in part to its poor penetration into bacteria, the way in which it inhibits DNA gyrase is unique. It therefore has the potential to guide the development of new, clinically relevant compounds acting against this enzyme, and the detailed...
structural information available should potentiate such development.

ACKNOWLEDGEMENTS
We thank Hans-Peter Fiedler for providing simocyclinone D8.

FUNDING
This work was funded by a BBSRC studentship to M.S., BBSRC grant BB/1002197/1 to M.J.B. and D.M.L., BBSRC grant BB/1002049/1 to A.M. and D.M.L. and by BBSRC Institute Strategic Programme Grant BB/J004561/1 to the John Innes Centre.

Conflict of interest. None declared.

REFERENCES
Ahn SK, Tahlan K, Yu Z et al. Investigation of transcription repression and small-molecule responsiveness by TetR-like transcription factors using a heterologous Escherichia coli-based assay. J Bacteriol 2007;189:6555–64.
Ald S, Mitchenall LA, Maxwell A et al. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics. J Antimicrob Chemother 2011;66:2061–9.
Anderle C, Hennig S, Kammerer B et al. Improved mutasynthetic approaches for the production of modified aminocoumarin antibiotics. Chem Biol 2007b;14:955–67.
Anderle C, Li SM, Kammerer B et al. New aminocoumarin antibiotics derived from 4-hydroxycinnamic acid are formed after heterologous expression of a modified chlorobiocin biosynthetic gene cluster. J Antimicrob Chemother 2007a;60:504–10.
Austin MJ, Healshaw SJ, Mitchenall LA et al. A natural product inspired fragment-based approach towards the development of novel anti-bacterial agents. MedChemComm 2016;7:1387–91.
Bax BD, Chan PF, Eggleston DS et al. Type IIa topoisomerase inhibition by a new class of antibacterial agents. Nature 2010;466:935–40.
Bilyk O, Brotz E, Tokovenko B et al. New Simocyclinones: surprising evolution and biosynthetic insights. ACS Chem Biol 2016;11:241–50.
Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1–12.
Bush K, Courvalin P, Dantas G et al. Tackling antibiotic resistance. Nat Rev Microbiol 2011;9:894–6.
Bush NG, Evans-Roberts K, Maxwell A. DNA topoisomerases. EcolSoc Plus 2015;6. http://www.ncbi.nlm.nih.gov/pubmed/26435256.
Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:232–60; second page, table of contents.
Clardy J, Fischbach MA, Walsh CT. New antibiotics from bacterial natural products. Nat Biotechnol 2006;24:1541–50.
Collin F, Karkare S, Maxwell A. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 2011;92:479–97.
Cundliffe E. How antibiotic-producing organisms avoid suicide. Annu Rev Microbiol 1989;43:207–33.
Cuthbertson L, Nodwell JR. The TetR family of regulators. Microbiol Mol Biol Rev 2013;77:440–75.
Dall’Acqua W, Carter P. Substrate-assisted catalysis: molecular basis and biological significance. Protein Sci 2000;9:1–9.
Edwards MJ, Flatman RH, Mitchenall LA et al. Crystalization and preliminary X-ray analysis of a complex formed between the antibiotic simocyclinone D8 and the DNA breakage-reunion domain of Escherichia coli DNA gyrase. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009a;F65:846–8.
Edwards MJ, Flatman RH, Mitchenall LA et al. A crystal structure of the bifunctional antibiotic simocyclinone D8, bound to DNA gyrase. Science 2009b;326:1415–8.
Edwards MJ, Williams MA, Maxwell A et al. Mass spectrometry reveals that the antibiotic simocyclinone D8 binds to DNA gyrase in a “bent-over” conformation: evidence of positive cooperativity in binding. Biochemistry 2011;50:3432–40.
Flatman RH, Howells AJ, Heide L et al. Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action. Antimicrob Agents Chemother 2005;49:1093–100.
Forterre P, Gribaldo S, Gadelle D et al. Origin and evolution of DNA topoisomerases. Biochimie 2007;89:427–46.
Galm U, Schimana J, Fiedler HP et al. Cloning and analysis of the simocyclinone biosynthetic gene cluster of Streptomyces antibioticus Tu 6040. Arch Microbiol 2002;178:102–14.
Harms A, Stanger FV, Scheu PD et al. Adenylation of gyrase and Topo IV by FicT toxins disrupts bacterial DNA topology. Cell Rep 2015;12:1497–507.
Hearshaw SJ, Edwards MJ, Stevenson CE et al. A new crystal structure of the bifunctional antibiotic simocyclinone D8 bound to DNA gyrase gives fresh insight into the mechanism of inhibition. J Mol Biol 2014;426:2023–33.
Heide L. Genetic engineering of antibiotic biosynthesis for the generation of new aminocoumarins. Biotechnol Adv 2009;27:1006–14.
Heide L. New aminocoumarin antibiotics as gyrase inhibitors. Int J Med Microbiol 2014;304:31–36.
Heide L, Gust B, Anderle C et al. Combinatorial biosynthesis, metabolic engineering and mutasynthesis for the generation of new aminocoumarin antibiotics. Curr Top Med Chem 2008;8:667–79.
Holzenkampfer M, Walker M, Zeeck A et al. Simocyclinones, novel cytostatic angucyclinone antibiotics produced by Streptomyces antibioticus Tu 6040 II. Structure elucidation and biosynthesis. J Antibiot (Tokyo) 2002;55:301–7.
Hopwood DA. How do antibiotic-producing bacteria ensure their self-resistance before antibiotic biosynthesis incapacitates them? Mol Microbiol 2007;63:937–40.
Itou H, Watanabe N, Yao M et al. Crystal structures of the multidrug binding repressor Corynebacterium glutamicum CgmR in complex with inducers and with an operator. J Mol Biol 2010;403:174–84.
Jiang H, Hutchinson CR. Feedback regulation of doxorubicin biosynthesis in Streptomyces peucetius. Res Microbiol 2006;157:666–74.
Kallberg Y, Oppermann U, Persson B. Classification of the short-chain dehydrogenase/reductase superfamily using hidden Markov models. FEBS J 2010;277:2375–86.
Kavanagh KL, Jornvall H, Persson B. Classification of the short-chain dehydrogenase/reductase gene and protein families: the SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes. Cell Mol Life Sci 2008;65:3895–906.
Laponogov I, Pan XS, Veselkov DA et al. Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS ONE 2010;5:e11338.
Laponogov I, Sohi MK, Veselkov DA et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol 2009;16:667–9.

Le TB, Fiedler HP, den Hengst CD et al. Coupling of the biosynthesis and export of the DNA gyrase inhibitor simocyclinone in Streptomyces antibioticus. Mol Microbiol 2009;72:1462–74.

Le TB, Schumacher MA, Lawson DM et al. The crystal structure of the TetR family transcriptional repressor SimR bound to DNA and the role of a flexible N-terminal extension in minor groove binding. Nucleic Acids Res 2011a;39:9433–47.

Le TB, Stevenson CE, Fiedler HP et al. Structures of the TetR-like simocyclinone efflux pump repressor, SimR, and the mechanism of ligand-mediated derepression. J Mol Biol 2011b;408:40–56.

Luft T, Li SM, Scheible H et al. Overexpression, purification and characterization of SimL, an amine synthetase involved in simocyclinone biosynthesis. Arch Microbiol 2005;183:277–85.

Maxwell A, Lawson DM. The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr Top Med Chem 2003;3:283–303.

McNicholas S, Potterton E, Wilson KS et al. Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr D Biol Crystallogr 2011;67:386–94.

Miller DJ, Zhang YM, Subramanian C et al. Structural basis for the transcriptional regulation of membrane lipid homeostasis. Nat Struct Mol Biol 2010;17:971–5.

Morais Cabral JH, Jackson AP, Smith CV et al. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 1997;388:903–6.

Oppegard LM, Hamann BL, Streek KR et al. In vivo and in vitro patterns of the activity of simocyclinone D8, an angucyclinone antibiotic from Streptomyces antibioticus. Antimicrob Agents Chemother 2009;53:2110–9.

Orth P, Saenger W, Hinrichs W. Tetracycline-chelated Mg2+ ion initiates helix unwinding in Tet repressor induction. Biochemistry 1999;38:191–8.

Orth P, Schnappinger D, Hillen W et al. Structural basis of gene regulation by the tetracycline inducible Tet repressor-operator system. Nat Struct Mol Biol 2000;7:215–9.

Ostash I, Ostash B, Luzhetsky A et al. Coordination of export and glycosylation of landomycins in Streptomyces cyanogenus S136. FEMS Microbiol Lett. 2008;285:195–202.

Otten SL, Ferguson J, Hutchinson CR. Regulation of daunorubicin production in Streptomyces peucetius by the dnrR2 locus. J Bacteriol 1995;177:1216–24.

Pacholec M, Freel Meyers CL, Oberthur M et al. Characterization of the aminocoumarin ligase SimL from the simocyclinone pathway and tandem incubation with NovM,P,N from the novobiocin pathway. Biochemistry 2005;44:4949–56.

Persson B, Källberg Y. Classification and nomenclature of the superfamily of short-chain dehydrogenases/reductases (SDRs). Chem Biol Interact 2013;202:111–5.

Pommier Y, Leo E, Zhang H et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17:421–33.

Ramos JL, Martinez-Bueno M, Molina-Henares AJ et al. The TetR family of transcriptional repressors. Microbiol Mol Biol Rev 2005;69:326–56.

Reichheld SE, Yu Z, Davidson AR. The induction of folding cooperativity by ligand binding drives the allosteric response of tetracycline repressor. P Natl Acad Sci USA 2009;106:22263–8.

Richter SN, Frasson I, Palumbo M et al. Simocyclinone D8 turns on against Gram-negative bacteria in a clinical setting. Bioorg Med Chem Lett 2010;20:1202–4.

Sadiq AA, Patel MR, Jacobson BA et al. Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II. Invest New Drugs. 2009.

Schäfer M, Le TB, Hearnsaw SJ et al. SimC7 Is a Novel NAD[P]H-dependent ketoreductase essential for the antibiotic activity of the DNA gyrase inhibitor simocyclinone. J Mol Biol 2015;427:2192–204.

Schäfer M, Stevenson CE, Wilkinson B et al. Substrate-assisted catalysis in polyketide reduction proceeds via a phenolone intermediate. Cell Chem Biol 2016;23:1091–7.

Schimana J, Fiedler HP, Groth I et al. Simocyclinones, novel cytostatic angucyclinone antibiotics produced by Streptomyces antibioticus Tu 6040. 1. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo) 2000;53:779–87.

Schimana J, Walker M, Zeeck A et al. Simocyclinones: diversity of metabolites is dependent on fermentation conditions. J Ind Microbiol Biotechnol 2001;27:144–8.

Schumacher MA, Miller MC, Grkovic S et al. Structural mechanisms of QacR induction and multidrug recognition. Science 2001;294:2158–63.

Schumacher MA, Miller MC, Grkovic S et al. Structural basis for cooperative DNA binding by two dimers of the multidrug-binding protein QacR. EMBO J 2002;21:1210–8.

Sissi C, Vazquez E, Chemello A et al. Mapping simocyclinone D8 interaction with DNA gyrase: evidence for a new binding site on GyrB. Antimicrob Agents Chemother 2010;54:213–20.

Tahan K, Ahn SK, Sing A et al. Initiation of actinorhodin export in Streptomyces coelicolor. Mol Microbiol 2007;63:951–61.

Tahan K, Yu Z, Xu Y et al. Ligand recognition by ActR, a TetR-like regulator of actinorhodin export. J Mol Biol 2008;383:753–61.

Theobald U, Schimana J, Fiedler HP. Microbial growth and production kinetics of Streptomyces antibioticus Tu 6040. Antonie Van Leeuwenhoek 2000;78:307–13.

Trefzer A, Pelzer S, Schimana J et al. Biosynthetic gene cluster of simocyclinone, a natural multihybrid antibiotic. Antimicrob Agents Chemother 2002;46:1174–82.

Vergheze J, Nguyen T, Oppegard LM et al. Flavone-based analogues inspired by the natural product simocyclinone D8 as DNA gyrase inhibitors. Bioorg Med Chem Lett 2013;23:5874–7.

Vos SM, Trettter EM, Schmidt BH et al. All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol 2011;12:827–41.

Wang JC. DNA topoisomerases. Annu Rev Biochem 1996;65:635–92.

Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430–40.

Willems AR, Tahan K, Taguchi T et al. Crystal structures of the Streptomyces coelicolor TetR-like protein ActR alone and in complex with actinorhodin or the actinorhodin biosynthetic precursor (5′)-DNA. J Mol Biol 2008;376:1377–87.

Yu Z, Reichheld SE, Savchenko A et al. A comprehensive analysis of structural and sequence conservation in the TetR family transcriptional regulators. J Mol Biol 2010;400:847–64.